Market Cap 15.29B
Revenue (ttm) 10.64B
Net Income (ttm) -649.00M
EPS (ttm) N/A
PE Ratio 11.46
Forward PE 11.91
Profit Margin -6.10%
Debt to Equity Ratio 1.43
Volume 5,596,100
Avg Vol 4,131,822
Day's Range N/A - N/A
Shares Out 513.18M
Stochastic %K 18%
Beta 0.61
Analysts Sell
Price Target $36.64

Company Profile

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed sy...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 224 948 2000
Address:
One Baxter Parkway, Deerfield, United States
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 19 at 2:19 PM
Baxter ($BAX) solidifies its position as a hemostats market leader with FLOSEAL™ and TISSEEL™, capitalizing on 5.92% CAGR growth through 2033. Surgical demand + aging populations create tailwinds, but watch pricing pressure in flowables segment. Their 23% market share looks defendable with new bioengineered gels in the pipeline. https://www.prnewswire.com/news-releases/hemostats-market-set-to-attain-valuation-of-us-4-839-million-by-2033-says-astute-analytica-302485998.html
0 · Reply
swingingtech
swingingtech Jun. 18 at 3:18 PM
$BAX https://wallstreetwaves.com/intriguing-bax-february-2026-options-puts-and-calls-analysis/
0 · Reply
swingingtech
swingingtech Jun. 11 at 3:11 AM
$APP $CVX $BAX https://wallstreetwaves.com/significant-options-trading-insights-for-app-cvx-and-bax-this-tuesday/
0 · Reply
TeresaTrades
TeresaTrades Jun. 10 at 7:00 PM
Heavy options volume $SJM $ENTG $BAX $ABCL $MOMO
0 · Reply
Gemineye
Gemineye Jun. 4 at 5:52 PM
$BAX anything under $30 was a gift if you haven’t been buying what are you waiting for?
0 · Reply
JackDarwin
JackDarwin Jun. 4 at 12:27 PM
$BAX Bullish Piercing Candlestick Pattern
0 · Reply
CrispDry
CrispDry Jun. 4 at 12:00 PM
$BAX big pop in pre market?
0 · Reply
Gemineye
Gemineye Jun. 3 at 4:14 PM
$BAX $29.70 GTC order filled yesterday another add
0 · Reply
OptionRunners
OptionRunners Jun. 2 at 5:43 PM
$BAX Buyer of the July 18th $30 calls 3,000 times for $1.25
0 · Reply
Stockgilde
Stockgilde May. 26 at 4:22 PM
$BAX - a cornerstone of U.S. national health security. - It controls over 70% of the IV solutions market in the U.S. - Baxter plays in an oligopoly—only a few big players dominate, and breaking in is nearly impossible. - No room for dreamer entrepreneurs or broke folks trying to squeeze in. - (Chart shows: as Baxter’s stock dropped, institutional investors ramped up their holdings—now at the highest level since the company was founded.)
0 · Reply
Latest News on BAX
The 'Goldilocks' Case For Baxter International

May 8, 2025, 10:16 AM EDT - 6 weeks ago

The 'Goldilocks' Case For Baxter International


Baxter Declares Quarterly Dividend

May 6, 2025, 4:15 PM EDT - 6 weeks ago

Baxter Declares Quarterly Dividend


Baxter Reports First-Quarter 2025 Results

May 1, 2025, 7:15 AM EDT - 7 weeks ago

Baxter Reports First-Quarter 2025 Results


Baxter to Host Annual Meeting of Stockholders in Virtual Format

Mar 26, 2025, 9:00 AM EDT - 3 months ago

Baxter to Host Annual Meeting of Stockholders in Virtual Format


Baxter Q4 Earnings Beat Expectations, Issues Strong 2025 Outlook

Feb 20, 2025, 12:41 PM EST - 4 months ago

Baxter Q4 Earnings Beat Expectations, Issues Strong 2025 Outlook


Baxter Reports Fourth-Quarter and Full-Year 2024 Results

Feb 20, 2025, 7:15 AM EST - 4 months ago

Baxter Reports Fourth-Quarter and Full-Year 2024 Results


Baxter to Present at TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 4:15 PM EST - 4 months ago

Baxter to Present at TD Cowen 45th Annual Health Care Conference


Baxter Announces CEO Retirement and Appointment of COO

Feb 3, 2025, 7:30 AM EST - 4 months ago

Baxter Announces CEO Retirement and Appointment of COO


Baxter to Present at 7th Annual Evercore HealthCONx Conference

Nov 19, 2024, 4:15 PM EST - 7 months ago

Baxter to Present at 7th Annual Evercore HealthCONx Conference


Baxter to Present at Jefferies London Healthcare Conference

Nov 13, 2024, 4:15 PM EST - 7 months ago

Baxter to Present at Jefferies London Healthcare Conference


Baxter to Present at Stifel 2024 Healthcare Conference

Nov 12, 2024, 4:15 PM EST - 7 months ago

Baxter to Present at Stifel 2024 Healthcare Conference


Baxter International Inc. (BAX) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 12:16 PM EST - 8 months ago

Baxter International Inc. (BAX) Q3 2024 Earnings Call Transcript


Baxter cuts annual profit forecast on hurricane impact

Nov 8, 2024, 7:35 AM EST - 8 months ago

Baxter cuts annual profit forecast on hurricane impact


Baxter Reports Third-Quarter 2024 Results

Nov 8, 2024, 7:15 AM EST - 8 months ago

Baxter Reports Third-Quarter 2024 Results


Baxter restarts IV solutions manufacturing line

Oct 31, 2024, 11:43 AM EDT - 8 months ago

Baxter restarts IV solutions manufacturing line


Baxter to Present at UBS Global Healthcare Conference

Oct 23, 2024, 4:15 PM EDT - 8 months ago

Baxter to Present at UBS Global Healthcare Conference


Baxter to import 18,000 tons of IV products to US by year-end

Oct 17, 2024, 1:15 PM EDT - 8 months ago

Baxter to import 18,000 tons of IV products to US by year-end


Baxter Is A Strong Buy: The Turnaround Story You Can't Ignore

Oct 14, 2024, 9:14 AM EDT - 8 months ago

Baxter Is A Strong Buy: The Turnaround Story You Can't Ignore


Does Baxter Stock Offer Any Room For Growth?

Oct 1, 2024, 8:00 AM EDT - 9 months ago

Does Baxter Stock Offer Any Room For Growth?


Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 19 at 2:19 PM
Baxter ($BAX) solidifies its position as a hemostats market leader with FLOSEAL™ and TISSEEL™, capitalizing on 5.92% CAGR growth through 2033. Surgical demand + aging populations create tailwinds, but watch pricing pressure in flowables segment. Their 23% market share looks defendable with new bioengineered gels in the pipeline. https://www.prnewswire.com/news-releases/hemostats-market-set-to-attain-valuation-of-us-4-839-million-by-2033-says-astute-analytica-302485998.html
0 · Reply
swingingtech
swingingtech Jun. 18 at 3:18 PM
$BAX https://wallstreetwaves.com/intriguing-bax-february-2026-options-puts-and-calls-analysis/
0 · Reply
swingingtech
swingingtech Jun. 11 at 3:11 AM
$APP $CVX $BAX https://wallstreetwaves.com/significant-options-trading-insights-for-app-cvx-and-bax-this-tuesday/
0 · Reply
TeresaTrades
TeresaTrades Jun. 10 at 7:00 PM
Heavy options volume $SJM $ENTG $BAX $ABCL $MOMO
0 · Reply
Gemineye
Gemineye Jun. 4 at 5:52 PM
$BAX anything under $30 was a gift if you haven’t been buying what are you waiting for?
0 · Reply
JackDarwin
JackDarwin Jun. 4 at 12:27 PM
$BAX Bullish Piercing Candlestick Pattern
0 · Reply
CrispDry
CrispDry Jun. 4 at 12:00 PM
$BAX big pop in pre market?
0 · Reply
Gemineye
Gemineye Jun. 3 at 4:14 PM
$BAX $29.70 GTC order filled yesterday another add
0 · Reply
OptionRunners
OptionRunners Jun. 2 at 5:43 PM
$BAX Buyer of the July 18th $30 calls 3,000 times for $1.25
0 · Reply
Stockgilde
Stockgilde May. 26 at 4:22 PM
$BAX - a cornerstone of U.S. national health security. - It controls over 70% of the IV solutions market in the U.S. - Baxter plays in an oligopoly—only a few big players dominate, and breaking in is nearly impossible. - No room for dreamer entrepreneurs or broke folks trying to squeeze in. - (Chart shows: as Baxter’s stock dropped, institutional investors ramped up their holdings—now at the highest level since the company was founded.)
0 · Reply
Gemineye
Gemineye May. 22 at 3:42 PM
$BAX 🧠 memory loss
0 · Reply
SteveJohnsonis
SteveJohnsonis May. 16 at 12:34 PM
0 · Reply
TalkMarkets
TalkMarkets May. 14 at 12:21 AM
“The Magic’s Still There” Stock Market (And Sentiment Results) $BAX $DIS $GXO https://talkmarkets.com/content/stocks--equities/the-magics-still-there-stock-market-and-sentiment-results?post=497338
0 · Reply
NJ125
NJ125 May. 12 at 2:03 AM
$BAX Anyone paying attention to controversy around the chemicals leaching from their IV bags and tubing into patient veins? Paying attention to California legislation change? Short?
0 · Reply
Gemineye
Gemineye May. 10 at 2:05 PM
$BAX as if you forgot?
0 · Reply
JarvisFlow
JarvisFlow May. 5 at 2:06 PM
Morgan Stanley has adjusted their stance on Baxter Intl ( $BAX ), setting the rating to Underweight with a target price of 30 → 28.
0 · Reply
SparkyReturns
SparkyReturns May. 2 at 8:47 PM
$ICU Dialysis machine companies like Fresenius are watching the AKI study. They may have to buy ICU at a huge premium to make up for future lost dialysis machine revenue. Nephros, Braun, and Baxter may also be interested. One day this will be amazing. Enjoy your weekend! $FMS $BAX $NEPH $DVA
2 · Reply
DonCorleone77
DonCorleone77 May. 1 at 12:22 PM
$BAX Baxter narrows FY25 adjusted EPS view to $2.47-$2.55 from $2.45-$2.55 Consensus $2.49. The company said, "Baxter now expects sales growth from continuing operations of 7% to 8% on a reported basis. On an operational basis, Baxter expects sales growth of 4% to 5%. The company now expects adjusted earnings from continuing operations, before special items, of $2.47 to $2.55 per diluted share, compared to prior guidance of $2.45 to $2.55 per diluted share."
0 · Reply
DonCorleone77
DonCorleone77 May. 1 at 12:21 PM
$BAX Baxter sees Q2 adjusted EPS 59c-63c, consensus 61c The company said, "The company expects sales growth from continuing operations of 4% to 5% on a reported basis and 1% to 2% on an operational basis. The company expects adjusted earnings from continuing operations, before special items, of $0.59 to $0.63 per diluted share."
0 · Reply
DonCorleone77
DonCorleone77 May. 1 at 12:21 PM
$BAX Baxter reports Q1 adjusted EPS 62c, consensus 48c Reports Q1 revenue $2.63B, consensus $2.59B. "Our solid performance in the first quarter of 2025 reflects the ongoing impact of our transformation journey," said Brent Shafer, chair and interim chief executive officer. "Baxter today is a more focused and agile organization, well positioned to drive enhanced value for patients, healthcare providers, customers and shareholders through our reinvigorated emphasis on execution, innovation and profitable growth. While today's global macroeconomic factors are creating a greater degree of uncertainty in the market, we remain confident in our overarching trajectory. The benefits of our operating model in combination with our durable portfolio of medically essential products create a strong foundation to leverage our potential and pursue opportunities to help address our customers' most pressing needs in the pursuit of our life-sustaining Mission."
1 · Reply
OpenOutcrier
OpenOutcrier May. 1 at 12:07 PM
$BAX (+4.9% pre) Baxter Non-GAAP EPS of $0.55 beats by $0.07, revenue of $2.63B beats by $40M https://ooc.bz/l/63139
0 · Reply
Longaeva_Capital
Longaeva_Capital May. 1 at 11:36 AM
$BAX
0 · Reply